Collegium Pharmaceutical Inc Dossier - Source-backed chat

Collegium Pharmaceutical Inc

COLLNASDAQ

SectorHealth Care

IndustryDrug Manufacturers - Specialty & Generic

Beta (adjusted)0.84

Intrinsic Value $29.08median of 5 methods · middle span $28-$46based on filings through 30 Jun 2026

Market Price $21.84Price as of 1 Oct 2026

UndervaluedIntrinsic value is 33% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $677M

Enterprise Value $1.4B

Shares Outstanding 31M diluted

Moat Rating Wide

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Collegium Pharmaceutical is successfully transitioning from a mature, cash-generative pain management business into a diversified biopharmaceutical company with a high-growth neuropsychiatry franchise. The primary growth engine is JORNAY PM, an evening-dosed ADHD treatment that continues to achieve record prescriptions and prescriber counts. This organic momentum is highly complemented by the pending $650 million acquisition of AZSTARYS, which is expected to close in Q2 2026, extend revenue durability into the late 2030s, and be immediately accretive to Adjusted EBITDA. Trading at a significant discount to its intrinsic value and historical multiples, Collegium offers a compelling risk-reward profile backed by robust cash generation and disciplined capital allocation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$43.00

Mean target$51.20

High · most bullish analyst$60.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$43.0010%

The integration of AZSTARYS faces operational delays or higher-than-anticipated commercialization costs, limiting near-term accretion. Branded pain products experience faster-than-expected generic erosion from authorized generics, and gross-to-net (GTN) discounts for JORNAY PM widen due to aggressive payer negotiations, squeezing operating margins and slowing down the company's deleveraging timeline.

Base CaseCentral scenario

$51.2060%

Matches the consensus mean

Collegium successfully closes the AZSTARYS transaction in Q2 2026 and delivers on its reaffirmed standalone 2026 guidance (total product revenues of $805M to $825M and Adjusted EBITDA of $455M to $475M). JORNAY PM remains the primary organic growth driver with net revenues reaching the guided $190M to $200M range. The pain portfolio experiences typical mature-phase dynamics but remains highly cash-generative, supporting debt service and ongoing capital deployment.

Bull CaseUpside scenario

$60.0030%

The acquisition of AZSTARYS closes smoothly in Q2 2026 and achieves rapid commercial integration, generating over $50 million in pro forma net revenues in H2 2026 and capturing significant cost synergies. JORNAY PM continues its steep upward trajectory, exceeding the high end of full-year guidance. Meanwhile, the pain portfolio remains highly durable, and the authorized generic tapentadol launch with Hikma yields higher-than-expected profit shares, driving substantial margin expansion and accelerating share buybacks.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong organic growth of JORNAY PM, with Q1 2026 net revenue up 36% year-over-year, driven by record prescriptions and an expanding prescriber base.
Highly strategic, immediately accretive acquisition of AZSTARYS, which expands the ADHD portfolio and extends revenue durability into 2037.
Robust cash generation and financial health, exiting Q1 2026 with $421.8 million in cash, cash equivalents, and marketable securities.

Key Investment Risks

Concentration and generic erosion risks within the mature pain portfolio, particularly tapentadol (Nucynta franchise).
Reliance on third-party manufacturers and suppliers for key product ingredients and commercial inventory.
Payer and reimbursement pressures that could negatively impact gross-to-net (GTN) margins for ADHD therapies.

Thesis Invalidation Triggers

Failure to close or successfully integrate the AZSTARYS acquisition within the projected timeline.
A sharp decline in JORNAY PM prescription growth or a significant deterioration in its gross-to-net margin below the mid-60% range.
Unexpected regulatory or supply chain disruptions that halt the manufacturing of core commercial products.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.